MRI markers of neuroinflammation in untreated patients with subclinical generalized anxiety disorder

TL;DR

This study finds evidence of neuroinflammation in the amygdala of untreated subclinical generalized anxiety disorder patients using MRI markers.

Contribution

The study identifies elevated neuroinflammatory markers in the amygdala of sub-GAD patients, linking them to anxiety severity.

Findings

Sub-GAD patients showed elevated inflammatory MRI markers in the amygdala compared to controls.

DBSI-RF values in the amygdala correlated with anxiety severity but not depression scores.

No significant changes were observed in the hippocampus or neocortex.

Abstract

Generalized Anxiety Disorder (GAD) is characterized by excessive worry and physical symptoms of prolonged anxiety. Patients with subclinical GAD-states (sub-GAD) do not fulfill the diagnostic criteria of GAD, but they often show a disease burden similar to GAD, and the subclinical state may turn into a full syndrome. Neuroinflammation may contribute to changes in brain structures in sub-GAD, but direct evidence remains lacking. We investigated 73 newly recruited sub-GAD patients who had never received pharmacological or psychological treatment and 64 matched non-clinical individuals. We utilized magnetic resonance imaging (MRI) to assess putative neuroinflammatory markers (DBSI-RF, diffusion-based spectral imaging-based restricted fraction) in the hippocampus, amygdala, and neocortex. The patients completed the Hamilton Anxiety Rating Scale (HAM-A), the Generalized Anxiety Disorder 7-item scale (GAD-7), and the Beck Depression Inventory-II (BDI-II). Compared to controls, sub-GAD individuals had significantly elevated inflammatory MRI markers in the amygdala but not in the hippocampus and neocortex. The DBSI-RF values correlated with the severity of anxiety (HAM-A and GAD-7 scores), but not with BDI-II. These findings suggest that neuroinflammation in the amygdala may play a critical role in the development of anxiety in sub-GAD.

Figures